ShareValue scores for 688828.SHG: Valuation 36, Quality 28, Growth 57, Health 37.
688828.SHGSSE
CIQTEK Co., Ltd.
CN¥69.49
(+1.56%)
Updated
688828.SHGSSE
CIQTEK Co., Ltd.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs Shanghai-listed Technology stocks
Company Details
CIQTEK Co., Ltd. engages in research and development, manufacturing, and sells magnetic resonance equipment, sensors, analytical instruments, optical equipment, mechanical equipment, and instrumentation equipment. It offers quantum information technology, includes wide-field NV microscope 1, scanning NV probe microscope, quantum diamond single spin spectrometer, quantum spin magnetometer; and spin resonance series, includes X-band continuous wave electron paramagnetic resonance spectrometer EPR200-Plus, X-band pulsed electron paramagnetic resonance spectrometer EPR100, W-band pulsed electron cyclomagnetic resonance spectrometer EPR-W900, benchtop electron paramagnetic resonance spectrometer EPR200M; Quantum computing series, a computing device that utilizes the principles of quantum superposition and entanglement to achieve exponential speedups in solving specific complex problems. It also provides products, including scanning NV probe microscopes, field emission scanning electron microscopes, and focused ion beam electron beam dual-beam microscopes. The company serves quantum technology, materials science, chemical engineering, biomedicine and advanced manufacturing fields. The Company was founded in 2016 and is based in Hefei, China.
Score Analysis
AI Investment Thesis
CIQTEK Co., Ltd. is overvalued: its P/S of 29.9 is higher than 94% of Shanghai-listed Technology peers, while P/E and PEG are not available.
Quality is the weak pillar: the -7.14% margin sits far below the 1.0% global sector average, and 2026 first-nine-month net loss widened to CN¥146 million on CN¥404 million revenue.
The 27 October 2026 third-quarter report showed revenue up 53.35% year on year but a CN¥76 million quarterly net loss, with R&D spending up 74%.